No proton pump inhibitors?

Infants and proton pump inhibitors: tribulations, no trials.

In this issue of the Journal, Barron et al (1) report their retrospective analysis of data from 4 US health plans, in which they document an enormous rise in the use of proton pump inhibitors (PPIs) in infants for presumed gastroesophageal reflux disease (GERD): In the 4 years from 2000 through 2003 there was at least a 4-fold increase, and in the 6 years from 1999 through 2004, there was a >7-...

Proton Pump Inhibitors: Omeprazole

Oral Proton Pump Inhibitors

There is currently a lack of evidence to suggest superior clinical efficacy of one oral proton pump inhibitor over any other. Proton pump inhibitors display similar doseresponse relationships with similar potencies and efficacies at the equivalent dose. The decision to select one proton pump inhibitor over another is likely to be based on the agents’ licensed indication, patient tolerability an...

Intravenous proton pump inhibitors.

Intravenous (IV) administration of a proton pump inhibitor (PPI) is a faster way to achieve gastric acid suppression than oral administration of the same agent. Peak suppression after IV administration occurs within hours, compared with several days later after oral administration. Thus the IV route of administration offers a faster onset of gastric suppression, achievement of intragastric pH c...

Proton Pump Inhibitors in Pediatrics

Proton pump inhibitors (PPIs) have become some of the most frequently prescribed medications for treatment of adults and children. Their effectiveness for treatment of peptic conditions in the pediatric population, including gastric ulcers, gastroesophageal reflux disease (GERD), and Helicobacter pylori infections has been established for children older than 1 year. Studies of the preverbal pop...